

REFERENCES

Abshire T, Kenet G. (2004) Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. *J Thromb Haemost*; 2:899-909.

Aeschlimann D, Paulsson M. (1994) Transglutaminases: protein cross-linking enzymes in tissues and body fluids. *Thromb Haemost* 71:402-15.

Agnelli G, Parise P, Levi M, Cosmi B, Nenci GG.(1995) Effects of desmopressin on hemostasis in patients with liver cirrhosis. *Haemostasis* 25:241-7.

Ahonen J, Jokela R.(2005) Recombinant factor VIIa for life-threatening post-partum haemorrhage. *Br J Anaesth* 94:592-5.

Aledort LM. (2004);Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. *J Thromb Haemost* 2:1700-8.

Allford SL, Hunt BJ, Rose P,(2003) on behalf of the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. *Br J Haematol* 120:556-73.

Almeida AM et al. (2003); The use of recombinant factor VIIa in children with inherited platelet function disorders. *Br J Haematol* 121:477-81.

Anita Aggarwal, Vera Malkovska, Joseph P Catlett and Kirsten Alcorn. 2004, *Thrombosis Journal* 2:9 doi:10.1186/1477-9560-2-9

Ardissino D, Merlini P, Ariens R, Coppola R, Bramucci E, Mannucci PM:(1997) Tissue-factor antigen and activity in human coronary atherosclerotic plaques. *Lancet*, 349:769-771.

Armand R, Hess JR. (2003)Treating coagulopathy in trauma patients. *Transfus Med Rev*;17:223-31.

Arts DG, de Keizer NF, Vroom MB,de Jong E.(2005); Reliability and accuracy of Sequential Organ Failure Assessment (SOFA) scoring. *Crit Care Med* 33:1988-93

Ashley C. W. Pike, Andrzej M. Brzozowski, Shirley M.(1999), Roberts, Ole H. Olsen†, And Egon Persson *Proc. Natl. Acad. Sci. USA*, Vol. 96, pp. 8925–8930, August 8925

Badimon J, Zaman A, Helft G, Fayad Z, Fuster V:(1999), Acute coronary syndromes: pathophysiology and preventive priorities. *Thromb Haemost* 82:997-1004.

Baglin TP, Keeling DM, Watson HG,(2006) for the British Committee for Standards in Haematology. Guidelines on oral anticoagulation. *Br J Haematol* (warfarin): third edition--2005 update. 132:277-85.

Beierlein W, Scheule AM, Dietrich W, Ziemer G.(2005) Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions. *Ann Thorac Surg* 79(2):741-8.

Berndt, M.C. (2004): Platelet receptors. Paper presented at: XVII congress of the International Society on Thrombosis and Haemostasis. Accessed November; 20.

Berrettini M, Mariani G, Schiavoni M, et al.(2001) Pharmacokinetic evaluation of recombinant, activated factor VII in patients with Inherited factor VII deficiency. *Haematologica*; 86:640– 645.

Biss TT, Hanley JP:(2007) Use of recombinant activated factor VII in the management of intractable haemorrhage: A survey of current UK practice. *Br J Haematol* 138:126-128,

Blatt, J., et al., (2001)Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. *Bone Marrow Transplantation*,. **28**(4): p. 405-7.

Blood component preparation, storage, shipping, and transportation. In: Vengelen-Tyler V, ed. *Technical Manual*. Bethesda, MD:American Association of Blood Banks, **1999**; 161-91.

Boffard K, Warren B, Iau P, et al.(2004) Decreased transfusion utilization and improved outcome associated with the use of recombinant factor VIIa as an adjunct in trauma. *J Trauma*;57:451.

Boffard KD, Riou B, Warren B, et al.(2005)Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. *J Trauma*; **59**: 8–18.

Boggio L, Green D. (2001);Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency. *Br J Haematol* 112(4):1074–1075.

Bombeli T, Spahn DR.(2004)Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhage. *Br J Anaesth* 93:275-87.

Bosch J, Thabut D, Bendtsen F, et al.(2004) Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: A randomized, double-blind trial. *Gastroenterology* 127: 1123-1130,

Bowles , C. J. Callaghan et al.,(2006) Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage *British Journal of Anaesthesia* 97(4):476-481; doi:10.1093/bja/ael205

Bowles KM, Callaghan CJ, Taylor AL:(2006)Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage. *Br J Anaesth* 97:476-481,

British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. *Br J Haematol* (2003) 122:10-23.

Carr Jr ME, Martin EJ:(2004).Recombinant factor VIIa: Clinical applications for an intravenous hemostatic agent with broadspectrum potential. *Expert Rev Cardiovasc Ther* 2:661-674,

Casati V, Bellotti F, Gerli C, et al.(2001).Tranexamic acid administration after cardiac surgery: a prospective, randomized, double-blind, placebocontrolled study. *Anesthesiology*;94(1):8-14.

Chuansumrit A, Wangruangsatid S, Lektrakul Y, et al. (2005) Control of bleeding in children with dengue hemorrhagic fever using recombinant activated factor VII: A randomized, doubleblind, placebo-controlled study. *Blood Coagul Fibrinolysis* 16: 549-555,

Ciavarella D, Reed RL, Counts RB, et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. *Br J Haematol* 1987;67:365–8.

Clark AD,Gordon WC,Walker ID,Tait RC. (2004)'last-ditch' use of recombinant factor Vlla in patients with massive haemorrhage is ineffective. *Vox Sang* 86:120-4

Coats T, Roberts I, Shakur H. (2004) Antifibrinolytic drugs for acute traumatic injury. *Cochrane Database Syst Rev* Oct 18;(4):CD004896.

Como JJ, Dutton RP, Scalea TM, Edelman BB, Hess JR:(2004) Blood transfusion rates in the care of acute trauma. *Transfusion*, 44:809-813.

Cosgriff N, Moore EE, Sauaia A, et al.(1997) Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidosis revisited. *J Trauma*;42:857-61.

d'Oiron R et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. *Thromb Haemost* 2000;83:644-47.

Development Task Force of the College of American Pathologists. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. *Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines. JAMA* (1994) 271:777-81.

Di Benedetto P, Baciarello M, Cabetti L, et al.(2003) Thrombelastography. Present and future perspectives in clinical practice. *Minerva Anestesiol*;69:501-15.

Dietrich W, Spath P, Zuhlsdorf M, et al.(2001) Anaphylactic reactions to aprotinin reexposure in cardiac surgery: relation to antiaprotinin immunoglobulin G and E antibodies. *Anesthesiology*;95(1):64-71.

Dietrich, W. and M. Spannagl,(2002) Caveat Against the Use of Activated Recombinant Factor VII for Intractable Bleeding in Cardiac Surgery. *Anesth Analg.* 94: p. 1365-76.

Diprose P, Herbertson MJ, O'Shaughnessy D, et al(2005): Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: Randomized double-blind placebo-controlled pilot study. *Br J Anaesth* 95:596-602,

Dory Jeweleicz, Julia Zaias, et al(2002) Early Injection of High-dose Recombinant factor VIIa Decreases Blood Loss and prolongs Time from Injury to Death in Experimental Liver Injury *J Trauma*. 53:1053-1057

Dougald M. Monroe, Harold R..(2003) Roberts Arterioscler Thromb Vasc Biol;23:8-9

Drummond JC, Petrovitch CT. The massively bleeding patient. *Anesthesiol Clin North America* 2001;19:633-49.

Dutton RP, Hess JR, Scalea TM.. (2003) Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients. *J Clin Anesth*;15:184 –188.

Dzik WH.(2004) Predicting hemorrhage using preoperative coagulation screening assays. *Curr Hematol Rep*;3:324-30.

Eskandari N, Feldman N, Greenspoon JS.(2002) Factor VII deficiency in pregnancy treated with recombinant factor VIIa. *Obstet Gynecol*;99(5 Pt 2):935–937.

F. Boehlen, M. Morales, P. Fontana et al.(2004) Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: Case report and review of the literature. *BJOG*; 111(3): 284 -87

Faringer PD, Mullins RJ, Johnson RL, Trunkey DD.(1993) Blood component supplementation during massive transfusion of AS- 1 red cells in trauma patients. *J Trauma*;34:481-5.

Ferrara A, MacArthur JD et al., (1990) Hypothermia and acidosis worsen coagulopathy in the patient requiring massive transfusion. *Am J Surg*;160: 515-8.

Freston, J.W. (2002): Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events. *Am. J. Med.*, 107:78-88.

Friederich PW et al.(2003) Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. *Lancet*; 361:201-205.

Friederich, P.W., et al., (2001) Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. *Circulation*,. 103: p. 2555-9.

G. Price, J. Kaplan & G. Skowronski.(2004) Use of recombinant factor VIIa to treat life-threatening non-surgical bleeding in a postpartum patient. *British Journal of Anaesthesia*; 93: 298 -300

Gabriel DA, Li X, Monroe DM 3rd, Roberts HR.(2004) Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. *J Thromb Haemost*, 2:1816-1822.

Ganapathy, coagulopathy in trauma. Ind. J. Trauma. Anaesth. Crit. Care Vol. 8 No. 2, 2007.

Gando S, Nanzaki S, Sasaki S, Kemmotsu O.(1998) Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. *Thromb Haemost*; 79:1111-5.

Geerts WH, Code KI, Jay RM, Chen E, Szalai JP.(1994) A prospective study of venous thromboembolism after major trauma. *N Engl J Med*;331:1601-6.

Goodnough LT, Lublin DM, Zhang L, et al:(2004) Transfusion medicine service policies for recombinant factor VIIa administration. *Transfusion* 44:1325-1331,

Grounds M.(2003) Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review. *Blood Rev* 17((Suppl 1)):S11-21.

Grounds RM, Bolan C. (2005) Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings. *Crit Care* 9:S29-S36, (Suppl 5)

Gubler KD, Gentilello LM, Hassantash SA, Maier RV.(1994) The impact of hypothermia on dilutional coagulopathy. *J Trauma*;36: 847-51.

Guyton and Arthur C (2003): Hemostasis and blood coagulation. Textbook of medical physiology (8th. ed.). W. B Saunders company Philadelphia; 3: 390-99.

Haas S.(2003) Aprotinin—an allogeneic transfusion sparing drug [in German]. *Anesthesiol Intensivmed Notfallmed Schmerzther*; 38(1):38- 40.

Hagiwara A, Murata A, Matsuda T, Matsuda H, Shimazaki S. (2004) The usefulness of transcatheter arterial embolization for patients with blunt polytrauma showing transient response to fluid resuscitation. *J Trauma*; 57:271-6.

Hebert PC, Wells G, Blajchman MA, et al. (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med*340:409-17.

Hedner U, Erhardtsen E. (2002)Potential role for rFVIIa in transfusion medicine. *Transfusion*;42:114–124.

Hedner U, Glazer S, Pingel K, et al:(1988) Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. *Lancet* 2:1193,

Hedner U, Kisiel W:(1983) Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. *J Clin Invest* 71:1836-1841,

Hedner U.(2000) Recombinant coagulation factor VIIa: From the concept to clinical application in hemophilia treatment in 2000. *Semin Thromb Hemost*;26:363–366.

Hedner U.(2001)Recombinant factor VIIa as a hemostatic agent. *Semin Hematol*;38:43–47.

Hess JR, Holcomb JB, Hoyt DB.(2006) Damage control resuscitation: the need for specific blood products to treat the coagulopathy of trauma. *Transfusion*.;46:685-686.

Hillman J, Fridriksson S, Nilsson O, et al:(2002) Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. *J Neurosurg* 97:771-778,

Ho AM, Karmakar MK, Dion PW:, (2005) Are we giving enough coagulation factors during major trauma resuscitation? *Am Journal Surg* 190:479-484

Hoffman M, Monroe DM:(2001) A cell-based model of hemostasis. *Thromb Haemost* 85:958-965,

Hoffman M. (2003) A cell-based model of coagulation and the role of factor VIIa. *Blood Rev* 17((Suppl 1)):S1-5.

Hoffman M.(2003) Remodeling the blood coagulation cascade. J Thromb Thrombolysis;16:17-20. 24. Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost 2001;85:958-65.

Hoffman, M. and D.M. Monroe,(2002) The Action of High-Dose Factor VIIa (FVIIa) in a Cell-Based Model of Hemostasis. Seminars in Haematology,. 38(Suppl 12): p. 6-9.

Hoffman, R.; Benz, E.J.; Furie, B.; Cohen, H.J.(2002): Haematology : Basic principle and practice, 3rd edn. New York : Churchill Livingstone; 158:189.

Holcomb JB. (2004) Methods for improved hemorrhage control. Crit Care; 8 Suppl 2: S57–S60.

Hoots K:(2006) Challenges in the therapeutic use of a “socalled” universal hemostatic agent: Recombinant factor VIIa. Hematol Am Soc Hematol Educ Program 426-431,

Hoyt DB, Bulger EM, Knudson MM, et al.(2006) Death in the operating room: an analysis of a multi-center experience. J Trauma **1994**; 37: 426-32.

Hoyt DB.(2004) A clinical review of bleeding dilemmas in trauma. Semin Hematol;41:40-3.

Janet Birchall, Simon J. Stanworth et al..(2008) Transfusion Medicine Reviews, Vol 22, No 3 ,: pp 177-187

John R. Hess .(2007),blood and coagulation support in trauma care,American society of hematology.j hematology 67:756-8

John Taper, (2004)Professor James Wiley, Dr Stephen Fuller Recombinant Activated Factor VII for Adjunctive Hemorrhage Control in Trauma. J Trauma; 51: 431-439

Johnston TD, Chen Y, Reed RL.(1994).Functional equivalence of hypothermia to specific clotting factor deficiencies. J Trauma 37:413-7.

K.Sembulingam and Prema Sembulingam (2004): Haemostasis and blood coagulation textbook of essential of medical Physiology (2nd edition). JAYPEE (5):201-230.

Kamphuisen, P.W., et al.,(2002) Control of life-threatening bleeding with activated recombinant factor VII. American Journal of Medicine,. **112**(4): p. 332-3.

Kenet G, Walden R, Eldad A, et al:(1999) Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 354:1879,

Kessler CM.(2000) New products for managing inhibitors to coagulation factors: A focus on recombinant factor VIIa concentrate. Curr Opin Hematol; 7:408–413.

Key NS et al.(1998) Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (novoseven) in haemophiliacs with inhibitors. Thromb Haemost;80:912- 18.

Key NS:(2003) Recombinant FVIIa for intractable hemorrhage: more questions than answers. Transfusion 43:1649-1651,

Khamashta MA, Hughes GR.(2005): Antophospholipid antibody and antiphospholipid syndrome. Curr Opin Rheumatol 7:389-394.

Knutson F, Rider J, Franck V, et al.(1999) A new apheresis procedure for the preparation of high-quality red cells and plasma. Transfusion;39:565-71.

Krebs VE, Higuera C, Barsoum WK, Helfand R.(2006) Blood management in joint replacement surgery: what's in and what's out. *Orthopedics*;29(9):801-3.

Kuo JR, Chou TJ, Chio CC.(2004) Coagulopathy as a parameter to predict the outcome in head injury patients-analysis of 61 cases. *J Clin Neurosci*; 11:710-4.

Kushimoto S, Arai M, Aiboshi J, Harada N et al.,:(2003) The role of interventional radiology in patients requiring damage control laparotomy. *J Trauma*, 54:171-176.

Lan Power, Peter Kam (2003): Principles of physiology.for anaesthetist, blood. 1st ed. Oxford University, p. 245-248. *Lancet* 1997; 349:1498-504.

Lawson JH, Murphy MP.(2004) Challenges for providing effective hemostasis in surgery and trauma. *Semin Hematol*;41: 55-64.

Lethagen S.(1997) Desmopressin---a haemostatic drug: state-of-the-art review. *Eur J Anaesthesiol (Suppl)* 14:1-9.

Levi M et al.(2005) Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. *Crit Care Med*;33:883-90.

Levi M, Cromheecke ME, de Jonge E, et al.(1999) Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. *Lancet* 354:1940-7.

Levi M, Vink R, de Jonge E.(2003) Prevention and treatment of bleeding by pro-hemostatic treatment strategies. *Wien Med Wochenschr* 153:421-5.

Levy JH, Sypniewski E.(2004) Aprotinin: a pharmacologic overview. *Orthopedics*;27(6 Suppl):S653-8

Levy JH:(2003) Novel pharmacologic approaches to reduce bleeding. *Can J Anaesth*, 50:S26-S30.

Lindley CM, Sawyer WT, Macik BG, et al.(1994) Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. *Clin Pharmacol Ther*; 55:638–48

Lisman T, Adelmeijer J, Cauwenberghs S et al.(2005),. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. *J Thromb Haemost*; 3:742–51

Lodge JP, Jonas S, Jones RM, et al:(2005) Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. *Liver Transpl* 11:973-979,

Lotspeich-Steininger, C.A.; Stiene-Martin, E.A.; Koepke, J.A(2002): Assessment of haemostasis. In : Michael L. Bishop, Janet, L., Edward P. (eds.) *Clinical chemistry principles, procedures, correlations* 3rd ed. Philadelphia, New York Lippincott-Raven; 519-537. Quoted from : Lotspeich-Steninger C.A.; Stiene-Martin, E.A.; Koepke J.A.*Clinical hematology*, Philadelphia, J.B.Lippincott, 1992:593.

Lusher JM:(1998) Early treatment with recombinant factor VIIa results in greater efficacy with less product. *Eur J Haematol Suppl* 61:7-10,

Lynn M, Jeroukhimov I, Klein Y, Martinowitz U.(2002) Updates in the management of severe coagulopathy in trauma patients. *Intensive Care Med*;28:S241-S247.

MacLaren R, Weber LA, Brake H, et al: (2005) A multicenter assessment of recombinant factor VIIa off-label usage: Clinical experiences and associated outcomes. *Transfusion* 45: 1434-1442,

MacLeod J, Lynn M, McKenney MG, Jeroukhimov I, Cohn SM.(2004) Predictors of mortality in trauma patients. *Am Surg*; 70: 805-10.

MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M.(2003) Early coagulopathy predicts mortality in trauma. *J Trauma*; 55:39-44.

Mahdy AM, Webster NR.(2004) Perioperative systemic haemostatic agents. *Br J Anaesth*;93(6):842-58.

Malone DL, Dunne J, Tracy JK, Putnam AT et al.,(2003): Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. *J Trauma*, 54:898-905.

Mangano DT, Miao Y, Vuylsteke A, et al.(2007) Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. *JAMA*;297(5):471-9.

Mangano DT, Tudor IC, Dietzel C.(2006) The risk associated with aprotinin in cardiac surgery. *N Engl J Med*;354(4):353-65.

Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. *Br J Haematol* (1975) 30:81-93.

Mannucci PM, Tuddenham EGD.(2001) The hemophilias: From royal genes to gene therapy. *N Engl J Med*;344:1773–1779.

Martin A Schreiber, John B Holcomb, Ulla Hedner, Susan I Brundage, et al.,(2003) The Effect of Recombinant Factor VIIa on Noncoagulopathic Pigs with Grade V Liver Injuries *J Am Coll Surg*;196:691–697

Martinowitz U, Holcomb JB, Pusateri AE, et al:(2001) Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. *J Trauma* 50:721-729,

Martinowitz U, Kenet G, Segal E, et al.(2001) Recombinant activated factor VII for adjunctive hemorrhage control in trauma. *J Trauma*; **51**: 431–9.

Martinowitz U, Michaelsons M,(2005) on behalf of the Israeli Multidisciplinary RVIIA Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. *J Thromb Haemost* 3:640-8.

Martinowitz, U.,(2002)The Use of rFVIIa as an adjunct treatment for haemorrhage control in trauma and surgery. *Bloodline Reviews*,. **1**(4): p. 9-11.

Mathew P.(2004)The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics.A systematic review. *Thromb Haemost*; 92:738-46.

Mayer SA et al.(2005) Recombinant activated factor VII for acute intracerebral hemorrhage. *N Engl J Med*; 352:777-85.

Mayer SA,(2007)on behalf of the FAST Trial Steering Committee: Complications in patients with intracerebral hemorrhage treated with recombinant factor VIIa. *Neurology* 69:319-320,

McLeod BC.(1990) Myocardial infarction in a blood donor after administration of desmopressin. *Lancet* 336:1137-8.

Meng ZH, Wolberg AS, Monroe DM, Hoffman M.(2003) The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients.*J Trauma*; 55: 886–91.

Menzebach A, Cassens U, Van Aken H, Booke M.(2003) Strategies to reduce perioperative blood loss related to non-surgical bleeding. *Eur J Anaesthesiol* 20:764-70.

Mohr AM, Holcomb JB, Dutton RP, Duranteau J.(2005) Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma.*Crit Care*;9:Suppl 5, S37-42

Monroe DM, Hoffman M, Oliver JA, Roberts HR.(1997) Platelet activity of high-dose factor VIIa is independent of tissue factor. *Br J Haematol.*;99:542–547.

Moore EE. Thomas G. Orr(1996) Memorial Lecture. Staged laparotomy for the hypothermia, acidosis, and coagulopathy syndrome. *Am J Surg*; 172:405-10.

Murase M, Usui A, Tomita Y, et al.(1993) Nafamostat mesilate reduces blood loss during open heart surgery. *Circulation*; 88(5 Pt 2):II432-6.

Murray CJ, Lopez AD.(1997) Mortality by cause for eight regions of the world: Global Burden of Disease Study. *Lancet*;349: 1269-76.

Nicholson AA. (2004) Vascular radiology in trauma. *Cardiovasc Intervent Radiol*;27:105-20.

Nitu-Whallwey IC Lee CA and Brown SA (2004): The role of the platelet function analyser (PFA-100) in the characterisation of patients with Von-Willebrand factor and the ABO blood group, Textbook of Haemophilia. WB Saunders Company, London 9:298-302.

O'Neill PA, Bluth M, Gloster ES, et al.(2002) Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. *J Trauma*; 52: 400–5.

O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM.(2006) Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. *JAMA*;295(3):293-8.

O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al.(2004).Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. *Br J Haematol* 126:11-28.

Ozelo MC et al.(2005) Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome. *Ann Hematol*;84:816-22.

Pape H, Erhardtson E, Meyer C.(2006) Recombinant factor VIIa for lifethreatening hemorrhage in trauma patients: review of the literature. *Eur J Trauma*; 32(5):439-48.

Peden M, McGee K, Sharma G.(2002) The Injury Chart Book: A Graphical Overview of the Global Burden of Injuries. Geneva: World Health Organization,

Peng RY, Bongard FS.(1999) Hypothermia in trauma patients. *J Am Coll Surg*;188:685-96.

Peter FW, Benkovic C, Muehlberger T, et al.(2002) Effects of desmopressin on thrombogenesis in aspirin-induced platelet dysfunction. *Br J Haematol* 117:658-63.

Phillips GR III, Kauder DR, Schwab CW.(1994) Massive blood loss in trauma patients. The benefits and dangers of transfusion therapy. *Postgrad Med*;95:61-72.

Pihusch M, Bacigalupo A, Szer J, et al.(2005) Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. *J Thromb Haemost*; 3:1935–44

Popovsky MA.(2001) Transfusion-related acute lung injury. In: Popovsky MA, ed. *Transfusion Reactions*. Bethesda: AABB Press,.

R. Michael Grounds, Caroline Seebach, Christoph Knothe, Piotr Paluszkiwicz, Terry S et al.,(2006) *Intensive Care Med*; 21; 27

Reed RL, Bracey AWJ Jr, Hudson JD, et al.(1990) Hypothermia and blood coagulation: dissociation between enzyme activity and clotting factor levels. *Circ Shock* 32:141-52.

Reiss RF.(2000) Hemostatic defects in massive transfusion: rapid diagnosis and management. *Am J Crit Care*; 9:158-65.

Riou B, Landais P, Vivien B, Stell P, Labbene I, Carli P:(2001) Distribution of the probability of survival is a strategic issue for randomized trials in critically ill patients. *Anesthesiology*, 95:56-63.

Rizoli SB, Chughtai T..(2006) The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic hemorrhage. *Expert Opin Biol Ther*;6:73– 81.

Roberts HR, Monroe DM 3rd, Hoffman M.(2004) Safety profile of recombinant factor VIIa. *Semin Hematol*; **41**:101–8

Roberts HR, Monroe DM, Escobar MA.(2004) Current concepts of hemostasis: implications for therapy. *Anesthesiology*;100: 722-30.

Roberts HR, Monroe DM, White GC:(2004) The use of recombinant factor VIIa in the treatment of bleeding disorders. *Blood* 104:3858-3864,

Royston D.(1998) Aprotinin versus lysine analogues: the debate continues. *Ann Thorac Surg*;65(4 Suppl):S9-19.

Royston D.(1998) Blood-sparing drugs: aprotinin, tranexamic acid, and epsilon-aminocaproic acid. *Int Anesthesiol Clin* **(1995)** 33:155-79.

Salooja N, Perry DJ. (2001) Thrombelastography. *Blood Coagul Fibrinolysis*12:327-37.

Sato T, Tanaka K, Kondo C, et al.(1991) Nafamostat mesilate administration during cardiopulmonary bypass decreases postoperative bleeding after cardiac surgery. *ASAIO Trans*;37(3):M194-5.

Sauaia A, Moore FA, Moore EE, et al.(1995) Epidemiology of trauma deaths: a reassessment. *J Trauma*; 38:185-93

Saxon Ridley; B. Taylor; K. Gunning, (2007) Cont Edu *Anaesth Crit Care & Pain*; 7(4):116-121.

Schneider B, Schnells G, Trentz O, Tscherne H. Field study on the therapeutic value of Trasylol in traumatic shock [in German]. *Chirurg* 1976; 47(4):185-8.

Sculco TP, Baldini A, Keating EM.(2005) Blood management in total joint arthroplasty. *Instr Course Lect*; 54:51-66.

Shackford SR, Mackersie RC, Holbrook TL, et al (1993) The epidemiology of traumatic death. A population-based analysis. *Arch Surg*, 128:571-575.

Shami VM et al.(2003) Recombinant activated factor VII for coagulopathy in ful-minant hepatic failure compared with conventional therapy. *Liver Transpl*; 9:138-43.

Shander A, Goodnough LT, Ratko T, et al.(2005) Consensus recommendations for the off-label use of recombinant human factor VIIa therapy. *Pharm Ther* 30:644-58.

Simmons RL, Collins JA, Heisterkamp CA, et al. Coagulation disorders in combat casualties. I. Acute changes after wounding. II. Effects of massive transfusion. III. Post-resuscitative changes. *Ann Surg* 1969; 169:455-82.

Spahn DR, Cerny V, Coats TM, et al.(2007) Management of bleeding following major trauma: A European guideline [erratum published in *Crit Care*;24;11(2):414]. *Crit Care* 2007; 11(1):R17.

Spahn DR, Tucci MA, Makris M.(2005) Is recombinant FVIIa the magic bullet in the treatment of major bleeding? *Br J Anaesth*; 94:553–5

Spinella PC, Perkins JG, McLaughlin DF, et al.(2008) The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. *J Trauma*; 64(2): 286-94.

Stainsby D, Jones H, Milkins, et al, (2006) on behalf of the SHOT Steering Group. Serious Hazards of Transfusion. (Accessed March). Annual Report 2003.

Stanworth SJ, Birchall J, Doree CJ, et al:(2007) Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2: CD005011,

Staudinger T, Frass M, Rintelen C, et al.(1999) Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive Care Med 25:1105-10.

Stein DM, Dutton RP, O'Connor J, Alexander M, Scalea TM.(2005).Determinants of futility of administration of recombinant factor VIIa in trauma. J Trauma; 59: 609–15.

Steiner ME, Key NS:(2006) Use of recombinant activated factor VII in the management of medical and surgical bleeding: A critical review. Transfus Alternatives Transfus Med, 66-80, (Suppl 1)

Thomas A. Ratko, PhD, Joseph P. Cummings, and Karl A. Matuszewski, MS,(2004) PharmD 712 P&T • • Vol. 29 No. 11

Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, et al.:(1997), Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95:594-599.

Ulla Hedner (2005): Recombinant factor VIIa as a haemostatic agent. Blood Review, Vol. 1 Issue.4 p. 3-8.

Velmahos GC,Chahwan S, Falabella A, Demetriades D:(2000) Angiographic embolization for intraperitoneal and retroperitoneal injuries. World J Surg, 24:539-545.

Vincent JL, de Mendonca A, Cantraine F, et al.(1998) Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of multicenter, prospective study. Working group on "sepsis-related problems" of the European Society Of Intensive Care Medicine. Crit Care Med;26:1793-800

Walsh PN. Platelet coagulation-protein interactions. Semin Thromb Hemost 2004;30:461-71.

Weiskopf RB:(2007) Recombinant-activated coagulation factor VIIa : Current development. Vox Sang 92:281-288,

WHO 2000. Injury: a leading cause of the global burden of disease. Geneva, Switzerland: World Health Organization; 2000.

Wolberg AS, Meng ZH, Monroe DM, III, Hoffman M. A(2004) systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma;56: 1221-8.

Wong WY, Huang WC, Miller R, et al.(2000) Clinical efficacy and recovery levels of recombinant FVIIa in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency. Haemophilia;6:50–54.

Wun T, Paglieroni TG, Lachant NA.(1995). Desmopressin stimulates the expression of P-selectin on human platelets in vitro. J Lab Clin Med 126:401-9.

Yoshihara H, Yamamoto T, Mihara H.(1985) Changes in coagulation and fibrinolysis occurring in dogs during hypothermia. Thromb Res;37:503-12.